High-dimensional molecular profiling to identify molecular subtypes of cardiogenic shock patients based on immune dysregulation may enrich future clinical trial design and novel therapies.
Characterizing the immune and inflammatory 'host response' in cardiogenic shock through molecular subphenotyping offers a novel pathway to develop targeted therapies and improve the static 30-50% mortality rate.
Recent clinical and research efforts in cardiogenic shock (CS) have largely focussed on the restoration of the low cardiac output state that is the conditio sine qua non of the clinical syndrome. This approach has failed to translate into improved outcomes, and mortality has remained static at 30-50%. There is an unmet need to better delineate the pathobiology of CS to understand the observed heterogeneity of presentation and treatment effect and to identify novel therapeutic targets. Despite data in other critical illness syndromes, specifically sepsis, the role of dysregulated inflammation and immunity is hitherto poorly described in CS. High-dimensional molecular profiling, particularly through leukocyte transcriptomics, may afford opportunity to better characterise subgroups of patients with shared mechanisms of immune dysregulation. In this state-of-the-art review, we outline the rationale for considering molecular subtypes of CS. We describe how high-dimensional molecular technologies can be used to identify these subtypes, and whether they share biological features with sepsis and other critical illness states. Finally, we propose how the identification of molecular subtypes of patients may enrich future clinical trial design and identification of novel therapies for CS.
Buckel et al. (2023) conducted a review in Cardiogenic shock. High-dimensional molecular profiling to identify molecular subtypes of cardiogenic shock patients based on immune dysregulation may enrich future clinical trial design and novel therapies.